ライフサイエンスコーパス: vaginal

1 In patients with uterine and vaginal abnormalities, a work-up for associated renal an

2 Both vaginal and abdominal mesh procedures for vaginal vault

3 Modelling UTIs in vitro, human vaginal and bladder epithelial cells were challenged wit

4 fference in any outcome was observed between vaginal and, separately, abdominal mesh repair of vagina

5 In women with symptoms of vaginal and/or vulvar atrophy, lubricants in addition to

6 cial effects of probiotics in reducing oral, vaginal, and enteric colonization byCandida; alleviation

7 We explored topical vaginal application as an approach to initiate local ant

8 Vaginal atrophy and sexual interest and dysfunction impr

9 ation System sexuality subscales, changes in vaginal atrophy using a validated 4-point scale, and com

10 Vaginal atrophy, sexual interest, and sexual dysfunction

11 androgen signaling determine the position of vaginal attachment to the urethra.

12 Evidence suggests that specific vaginal bacteria associated with bacterial vaginosis (BV

13 This study provides evidence linking vaginal bacteria to microbicide efficacy through tenofov

14 ptive treatment (PPT) on detection of select vaginal bacteria.

15 Vaginal bacterial community structure and composition ex

16 Two major vaginal bacterial community types-one dominated by Lacto

17 In cross-sectional studies increased vaginal bacterial diversity has been associated with vag

18 s, and tissue samples (rectal, cervical, and vaginal) before and after exposure to long-acting rilpiv

19 unscheduled repeat CS with those that follow vaginal birth after CS (VBAC).

20 Offspring delivered via vaginal birth among women who had undergone a previous c

21 y sequential colonisation of i) intrauterine/vaginal birth associated taxa, ii) skin derived taxa and

22 eatment, did not result in higher rates of a vaginal birth of a healthy singleton at term within 24 m

23 The primary outcome was the vaginal birth of a healthy singleton at term within 24 m

24 ed via cesarean birth vs those delivered via vaginal birth was 1.15 (95% CI, 1.06-1.26; P = .002).

25 Vaginal birth within 24 h was more common in women in th

26 The primary outcome was vaginal birth within 24 h.

27 ure to maternal bowel flora during labour or vaginal birth, offspring delivered by CS may be adversel

28 DHT altered the duration of vaginal bleeding and delayed restoration of the luminal

29 Vaginal bleeding events were defined as any vaginal bleeding complications as reported by the patien

30 o investigate the management and outcomes of vaginal bleeding complications during therapy with direc

31 vide guidance on prevention and treatment of vaginal bleeding complications in this patient populatio

32 Vaginal bleeding events were defined as any vaginal blee

33 and mortality; and pattern and management of vaginal bleeding events.

34 rning urine specimens and recorded days with vaginal bleeding for up to 6 months.

35 Vaginal bleeding, particularly heavy menstrual bleeding,

36 r uterine segment with a history of painless vaginal bleeding.

37 load (VL) in 124 fluid samples (oral, urine, vaginal, blood) collected from 21 women who acquired CMV

38 vaginal intraepithelial neoplasia grade 2/3, vaginal cancer) related to HPV 31, 33, 45, 52, and 58 an

39 grade 3, 86.08 (95% CI, 11.98 to 618.08) for vaginal cancer, 25.65 (95% CI, 10.50 to 62.69) for vagin

40 es in currently used rat and mouse models of vaginal candidiasis have generated a large mass of data

41 Vaginal candidiasis is common during pregnancy.

42 ers, syphilis, bacterial vaginosis (BV), and vaginal candidiasis.

43 soy formula have altered DNA methylation in vaginal cell DNA which may be associated with decreased

44 most differentially methylated sites in 214 vaginal cell samples serially collected between birth an

45 evaluated epigenome-wide DNA methylation in vaginal cells from four soy formula-fed and six cow form

46 ociated with differential DNA methylation in vaginal cells from soy-fed infant girls.

47 aternal GBS colonization (GBS isolation from vaginal, cervical, and/or rectal swabs; with separate su

48 ch prechallenge correlate of protection from vaginal challenge has recently been identified as a syst

49 We show that vaginal challenge immediately elicits striking increases

50 macaque simian immunodeficiency virus (SIV) vaginal challenge model, we developed methodology to ide

51 ARV-based microbicide in a nonhuman primate vaginal challenge model.

52 nduced L2 antibodies and protected mice from vaginal challenge with an HPV16 pseudovirus.

53 geted version of the DNA can protect against vaginal challenge with HPV16, suggesting the promise of

54 he most robust protection against subsequent vaginal challenge with wild-type (WT) SIV in the SIV-rhe

55 ave increased susceptibility to a simian-HIV vaginal challenge), while the microbicide reduced the in

56 ion of the Ab component of this system after vaginal challenge.

57 to progestin-injectable use), but not recent vaginal cleansing, were significantly associated with mi

58 Vaginal CMV shedding may provide a route for sexual and

59 inding may contribute to the risk of E. coli vaginal colonization following sexual intercourse.

60 C7 attenuates gonococcal burden in the mouse vaginal colonization model.

61 ant advancements in our understanding of GBS vaginal colonization, ascending infection, and preterm b

62 ally during childbirth secondary to maternal vaginal colonization.

63 risk factor for neonatal disease is maternal vaginal colonization.

64 acterial communities within maternal gut and vaginal compartments can have an impact on directing the

65 heir entire reproductive lifespan, disrupted vaginal cycling, and hypergonadotropic hypogonadism.

66 rineal tear rate was reduced in out-of-hours vaginal deliveries (3.3% versus 3.6%, adj. OR 0.92; 95%

67 taying too short ranged from 0.2% to 83% for vaginal deliveries and from 1% to 75% for cesarean-secti

68 Compared with women having vaginal deliveries, fully adjusted multivariable analysi

69 ing during labor, we hypothesized that among vaginal deliveries, maternal body mass index is associat

70 ate of severe perineal tears in out-of-hours vaginal deliveries.

71 th a slightly increased risk of instrumental vaginal delivery (adjRR 1.06; 95% CI 1.01-1.11, P = 0.02

72 seropositivity (JCPyV, HPyV7, HPyV10, CMV), vaginal delivery (HPyV10), breastfeeding (CMV), younger

73 dren delivered by acute and elective CS with vaginal delivery as the reference were calculated by usi

74 ong the risk factors examined in this study, vaginal delivery compared with cesarean section (odds ra

75 ittle information is available regarding the vaginal delivery of larger and more polar molecules that

76 Vaginal delivery was associated with a significantly inc

77 , gestation <25 weeks, chorioamnionitis, and vaginal delivery were all strongly associated with EOD.

78 .14) or in the percentage of women who had a vaginal delivery with the use of forceps or vacuum (115

79 ed by its association with chorioamnionitis, vaginal delivery, and pneumonia.

80 OR = 1.11, 95% CI: 1.01, 1.22) compared with vaginal delivery, and the magnitude of the association w

81 in neonatal acquisition of microbiota during vaginal delivery, but not Cesarean delivery.

82 Compared with vaginal delivery, caesarean delivery had a protective as

83 Compared with spontaneous vaginal delivery, the adjusted risk ratio was 1.33 (95%

84 Cesarean delivery, as opposed to vaginal delivery, was associated with an increased risk

85 and 0.97 (95% CI: 0.84, 1.12) for operative vaginal delivery.

86 She was born at full term via spontaneous vaginal delivery.

87 group had a higher rate of increased or new vaginal discharge (86.7% vs 46.0%; between-group differe

88 y, patients on tamoxifen alone reported more vaginal discharge over the 5 years than patients on tamo

89 The incidence of new or increased vaginal discharge was significantly higher in the pessar

90 swabs (n=392) from symptomatic females with vaginal discharge.

91 ial neoplasia grade 2/3, vulvar cancer), and vaginal disease (vaginal intraepithelial neoplasia grade

92 incidence of high-grade cervical, vulvar and vaginal disease related to HPV 31, 33, 45, 52, and 58 wa

93 Bacterial vaginosis is the most common vaginal disorder in women, but current treatments are as

94 Clinically, vaginal-douche BD2 concentrations were reduced (p < 0.05

95 s that have examined the association between vaginal douching and genital human papillomavirus (HPV)

96 , oral mucosal, gastrointestinal, ungual and vaginal drug administration.

97 could provide an adaptable platform for the vaginal drug delivery of many molecules.

98 ptive users (n = 63), and women who practice vaginal drying (n = 46), were analyzed using tandem-mass

99 Vaginal drying associated with increased hemoglobin and

100 ide new insights into the impact of DMPA and vaginal drying on mucosal barriers.

101 aining Gardnerella vaginalis associated with vaginal drying, whereas DMPA showed no significant assoc

102 exacerbated in DMPA users who also practiced vaginal drying.

103 ductions in the frequency of hot flashes and vaginal dryness but no significant reduction in night sw

104 ence of changes, -0.79 [-1.35 to -0.23]) and vaginal dryness score (pooled mean difference of changes

105 st and sleep disturbance at 6 months, and by vaginal dryness up to 60 months.

106 d menopausal symptoms including hot flashes, vaginal dryness, and sexual dysfunction.

107 ge I to III BC taking AIs with self-reported vaginal dryness, dyspareunia, or decreased libido were r

108 al study confirms the inflammatory nature of vaginal dysbiosis and its association with recent vagina

109 f the pathophysiology of this unique form of vaginal dysbiosis has been a significant impediment to d

110 al-health-score as predictive biomarkers for vaginal dysbiosis merits further investigation.

111 oncurrent testing for bacterial vaginosis or vaginal dysbiosis.

112 and Vdelta2 showed comparable levels across vaginal, ectocervical, and endocervical tissues; however

113 We describe vaginal ectopic follicles that are structurally and func

114 rgan level (e.g., gastrointestinal tract and vaginal environment), tissue level (e.g., cancerous and

115 la and epigenetic modifications: analysis of vaginal epithelial cells from infant girls in the IFED s

116 Vaginal epithelial proliferation and lubrication after s

117 equire parenteral administration because the vaginal epithelium is perceived as a barrier to absorpti

118 Primary infection of the vaginal epithelium with C. muridarum produced infections

119 adherence to scavenger receptor gp340, human vaginal epithelium, and to the fungus Candida albicans C

120 The vaginal epithelium, in contrast, is not keratinized and

121 Topical vaginal estrogen treatment increased (p < 0.001) BD2 con

122 Low-dose vaginal estrogen, lidocaine, and dehydroepiandrosterone

123 Understanding the host immune response to vaginal exposure to RNA viruses is required to combat se

124 men with singleton pregnancies, quantitative vaginal fetal fibronectin and serial transvaginal ultras

125 lliparous women using serial measurements of vaginal fetal fibronectin levels and cervical length.

126 ransvaginal cervical length and quantitative vaginal fetal fibronectin levels were reviewed at 2 stud

127 A ureteric-vaginal fistula developed 2 weeks after uterus procureme

128 onjunctiva/tears (28 days), stool (29 days), vaginal fluid (33 days), sweat (44 days), urine (64 days

129 Vaginal fluid from 15 women was plated on 6 different me

130 During February 2005-February 2006, vaginal fluid specimens collected from women every other

131 Vaginal fluid specimens were collected via polyester/pol

132 The geometric mean VL of vaginal fluid was significantly higher than that of othe

133 with lower quantities of immune mediators in vaginal fluid.

134 We assessed maternal recto-vaginal GBS colonization (7,967 women), stillbirth and n

135 ber of studies on improving the retention of vaginal gels and modulating the controlled release of dr

136 s to quantify nine organisms associated with vaginal health or disease:Gardnerella vaginalis,Atopobiu

137 The role of PPT to improve vaginal health should be considered, and efforts to impr

138 mediators and IP-10 in combination with the vaginal-health-score as predictive biomarkers for vagina

139 A higher 'composite-qPCR vaginal-health-score' was directly associated with decre

140 d HPV testing) and any cervical, vulvar, and vaginal histopathological findings for all women residin

141 TDF PrEP prevented vaginal HIV acquisition in a dose-dependent manner.

142 rm a PK-PD analysis of systemic TDF PrEP for vaginal HIV acquisition.

143 ponses were coincident with a suppression of vaginal HSV-2 shedding, low lesion scores, and a reducti

144 n abdominal hysterectomy, 2513 (32.7%) had a vaginal hysterectomy, and 1458 (19.0%) had a laparoscopi

145 therapeutic and antibiotic sparing roles for vaginal immunomodulatory agents that specifically target

146 sal colonization but failed to induce robust vaginal immunopathology (neutrophil recruitment, interle

147 t the physiological contributions of SAPs to vaginal immunopathology require hypha formation, other h

148 w these marked differences in the biology of vaginal infection between these otherwise genetically si

149 om the United States and Kenya with a recent vaginal infection received intravaginal metronidazole 75

150 roup (19 [23%] vs three [4%], p=0.0005), but vaginal infections were less common (one [1%] vs eight [

151 riodic presumptive treatment (PPT) to reduce vaginal infections, we observed a significant reduction

152 bacterial diversity has been associated with vaginal inflammation which can be detrimental for health

153 e foci of SIV (mac239) infection 48 hr after vaginal inoculation.

154 ikely than other women to report unprotected vaginal intercourse (p = 0.026) or stimulant drug use (p

155 de 2/3, vulvar cancer), and vaginal disease (vaginal intraepithelial neoplasia grade 2/3, vaginal can

156 l cancer, 25.65 (95% CI, 10.50 to 62.69) for vaginal intraepithelial neoplasia grade 3, and 5.51 (95%

157 llected from term cesarean (not in labor) or vaginal (labor) deliveries, preterm premature rupture of

158 Vaginal lavage samples from nonpregnant women were teste

159 , sexual arousal (EST2 = .50; P = .008), and vaginal lubrication (EST2 = .46; P = .013).

160 Sexual Function Index scores for arousal and vaginal lubrication.

161 vasive reintervention after the placement of vaginal mesh for POP repair or SUI surgery.

162 epair with mesh and no concurrent sling use (vaginal mesh group), transvaginal POP repair without mes

163 rosion diagnosis was also the highest in the vaginal mesh plus sling group (2.13%; 95% CI, 1.76%-2.56

164 he highest risk of erosions was found in the vaginal mesh plus sling group (2.72%; 95% CI, 2.31%-3.21

165 surgery with mesh and concurrent sling use (vaginal mesh plus sling group), transvaginal POP repair

166 remain unclear, our results demonstrate that vaginal microbes can be partially restored at birth in C

167 thesis that maternal stress disrupts gut and vaginal microbial dynamics during critical prenatal and

168 At the same time, a vaginal microbicide gel formulation was developed and te

169 Preventing HIV transmission by the use of a vaginal microbicide is a topic of considerable interest

170 The composition of the vaginal microbiome and its influence on pregnancy outcom

171 ring pregnancy and transmission of dysbiotic vaginal microbiome at birth.

172 of these included better characterization of vaginal microbiome community state subtypes, application

173 We evaluated if the vaginal microbiome differed between women with a first o

174 Relative abundance of bacteria in the vaginal microbiome in first trimester pregnant women, 52

175 et al. (2017) reveal a putative role for the vaginal microbiome in modulating heterosexual transmissi

176 The composition of vaginal microbiome is important for reproductive success

177 acquisition, and genital inflammation or the vaginal microbiome may contribute to this risk.

178 functional profiling revealed three distinct vaginal microbiome subtypes, one of which was characteri

179 tors, including pathogenicity, host factors, vaginal microbiome, false-negative screening, and/or cha

180 Evidence suggests the vaginal microbiota (VM) may influence risk of persistent

181 tand the functional underpinnings of how the vaginal microbiota affect host physiology but also how h

182 itudinal changes at 5 visits over 8 weeks in vaginal microbiota and immune mediators in African women

183 lla vaginalis, and Neisseria gonorrhoeae All vaginal microbiota and N. gonorrhoeae efficiently coloni

184 and corroborate the association between the vaginal microbiota and PTB, demonstrate the benefits of

185 tly among women with abnormal versus healthy vaginal microbiota as defined by Nugent score.

186 characteristics, alpha-diversity, or overall vaginal microbiota community state type (CST).

187 ous studies have suggested that the maternal vaginal microbiota contributes to the pathophysiology of

188 Vaginal microbiota CST and alpha-diversity are not relat

189 We argue that the vaginal microbiota is better represented by the quantita

190 e interaction between the human host and the vaginal microbiota is highly dynamic.

191 Exposure of newborns to the maternal vaginal microbiota is interrupted with cesarean birthing

192 me species associated with non-Lactobacillus vaginal microbiota may trigger immune responses as well

193 We investigated whether vaginal microbiota modulated tenofovir gel microbicide e

194 The vaginal microbiota of reproductive-aged women is largely

195 However, the effect of abnormal vaginal microbiota on PrEP efficacy is of concern.

196 n de Wijgert discusses the latest on how the vaginal microbiota predisposes women to acquisition of S

197 Vaginal microbiota were assessed monthly and categorized

198 known about the relationship between GBS and vaginal microbiota.

199 ogy but also how host physiology affects the vaginal microbiota.

200 actobacillus spp./ BV-related species in the vaginal microflora of baboons (Papio spp.).

201 The differences in the vaginal milieu between NHP and humans might be the facto

202 or vulvar atrophy, lubricants in addition to vaginal moisturizers may be tried as a first option.

203 ement of innate-mediated inflammation in the vaginal mucosa rescues this phenotype and completely inh

204 we show that these viruses replicate in the vaginal mucosa with minimal induction of antiviral inter

205 Serum and vaginal mucosal fluids were sampled every two weeks and

206 deliver a protein vaccine formulation to the vaginal mucosal surface, we used a novel vaginal ring de

207 ected in both the intramuscularly-primed and vaginal mucosally-primed groups.

208 pair of vaginal vault prolapse compared with vaginal non-mesh repair.

209 a tumor-inducing level led to early onset of vaginal opening and to obesity in female CD-1 mice.

210 , exhibited early puberty, observed as early vaginal opening, larger litters, and early reproductive

211 We examined reproductive end points (age at vaginal opening, reproductive hormone levels, estrous cy

212 HIV-uninfected women reporting condomless vaginal or anal intercourse with at least 1 man with HIV

213 Mode of delivery (vaginal or cesarean section) is thought to affect gut mi

214 , and those who reported 16 or more lifetime vaginal or oral sex partners.

215 py (with azithromycin or doxycycline), anal, vaginal, or urine samples were self-collected during 28

216 ized in the contexts of social structure and vaginal pathology in non-human primates (NHPs).

217 le genital tract (FGT) microbiome may affect vaginal pH and other factors that influence drug movemen

218 Vaginal pH, concentrations of immune molecules, and anti

219 Major changes in the vaginal physiology and microbiota over a woman's lifetim

220 ective of the study was to determine whether vaginal progesterone prophylaxis given to reduce the ris

221 Vaginal progesterone was not associated with reduced ris

222 ind, randomised, placebo-controlled trial of vaginal progesterone, 200 mg daily taken from 22-24 to 3

223 horter, women in both groups were prescribed vaginal progesterone, 200 mg/d, until 36 weeks 6 days of

224 t subsequent visits, received treatment with vaginal progesterone.

225 se effects of mesh or graft reinforcement in vaginal prolapse surgery.

226 istein-exposed mice showed a 50% decrease in vaginal Prr5l mRNA levels compared to controls.

227 isolates prospectively sampled in 2014 from vaginal/rectal swabs of healthy pregnant women in metrop

228 Augmentation of a vaginal repair with mesh or graft material did not impro

229 INTERPRETATION: Augmentation of a vaginal repair with mesh or graft material did not impro

230 ctiveness and complication rates to non-mesh vaginal repair.

231 terone cream (IVT) or an estradiol-releasing vaginal ring (7.5 mug/d) in patients with early-stage br

232 rolmin), 2.0 (95% CI, 1.76-2.18); users of a vaginal ring (etonogestrel), 1.6 (95% CI, 1.55-1.69); an

233 2 elevation was seen in 4 of 35 (11%) with a vaginal ring and in 4 of 34 (12%) with IVT.

234 ent E2 elevation was observed in none with a vaginal ring and in 4 of 34 women (12%) with IVT.

235 the safety and efficacy of extended use of a vaginal ring containing dapivirine for the prevention of

236 the vaginal mucosal surface, we used a novel vaginal ring device comprising a silicone elastomer body

237 oducts, including a multi-purpose technology vaginal ring device offering simultaneous release of lev

238 as to evaluate safety of IVT or an estradiol vaginal ring in patients with early-stage BC receiving a

239 rly-stage BC receiving AIs, treatment with a vaginal ring or IVT over 12 weeks met the primary safety

240 djuvanted antigen formulation within a novel vaginal ring vaccine release device.

241 n-only products, 2.58 (95% CI=2.06-3.22) for vaginal ring, and 3.28 (95% CI=2.08-5.16) for patch.

242 andomized to 12 weeks of IVT or an estradiol vaginal ring.

243 ger-acting methods of drug delivery, such as vaginal rings, may simplify use of antiretroviral medica

244 Prompt delivery, preferably by the vaginal route, is vital for good maternal and neonatal o

245 We applied DADA2 to vaginal samples from a cohort of pregnant women, reveali

246 Cervico-vaginal samples were collected with cytobrush and rayon

247 Bacterial community profiles in vaginal samples were determined using broad-range 16S rR

248 artially concordant for 9 of the 15 cervical-vaginal samples, with 95.83% overall type-specific conco

249 late with Env-specific antibody responses in vaginal secretions and protection against infection.

250 Vaginal secretions contain chemokines that drive neutrop

251 e collected serum, urine, saliva, semen, and vaginal secretions weekly for the first month and then a

252 cific antibody responses in the serum and in vaginal secretions.

253 of Env-specific IgG antibodies in serum and vaginal secretions.

254 al fluid (CSF) and semen, but transiently in vaginal secretions.

255 cipants had detectable ZIKV RNA in saliva or vaginal secretions.

256 edictors of concordance were days since last vaginal sex (26.5% higher concordance 0-1 vs 8-14 days a

257 al dysbiosis and its association with recent vaginal sex and progestin-injectable use.

258 ions in genital samples were attributable to vaginal sex in the past week.

259 ficantly decreased as the lifetime number of vaginal sex partners increased (Pinteraction = .037).

260 Unprotected vaginal sex results in a reduction in endogenous anti-E.

261 gher concordance 0-1 vs 8-14 days after last vaginal sex) and condom use (22.6% higher concordance in

262 essed HIV-1 RNA viral load for both anal and vaginal sex.

263 may be depositions due to recent unprotected vaginal sex.

264 As determined by vaginal shedding, HLA-DR4 mice were more susceptible to

265 As determined by severity and length of vaginal shedding, WT C57BL/6 and HLA-DR4 mice were signi

266 ques from developing AIDS and partially from vaginal SIV acquisition.

267 We investigated vaginal size, vulvovaginal pathology and the presence of

268 n of bacterial morphotypes of a Gram-stained vaginal smear (i.e., Nugent scoring).

269 We analyzed 385 vaginal specimens collected prospectively from subjects

270 , forehead, mouth, rectal, semen, urine, and vaginal specimens for presence of Ebola virus using RT-P

271 een these species in their ability to infect vaginal squamous epithelial cells in vivo independently

272 C. muridarum readily colonized and infected vaginal squamous epithelial cells, whereas C. trachomati

273 gradient and favors neutrophil arrest in the vaginal stroma; as a result, the vagina becomes more vul

274 Oral rinse, penile swab, and vaginal swab specimens were evaluated by polymerase chai

275 performance for women using endocervical and vaginal swabs as well as urine specimens.

276 profiled the taxonomic composition of 2,179 vaginal swabs collected prospectively and weekly during

277 = 64 from a total of 12,776), and evaluated vaginal swabs using polymerase chain reaction (PCR) (gro

278 V sensitivity was 96.1% (91.7% to 98.2%) for vaginal swabs, 93.4% (88.3% to 96.4%) for endocervical s

279 8% to 95.1%), and 96.1% (92.2% to 98.1%) for vaginal swabs, endocervical swabs, female urine samples,

280 ears vs 0.65 for age >/=60 years; p=0.0006), vaginal symptoms (0.98 vs 0.65; p<0.0001), weight proble

281 Secondary outcomes were vaginal symptoms and sexual functioning.

282 t anaerobes and is sometimes associated with vaginal symptoms.

283 tive cohort study of first-time tension-free vaginal tape (TVT), trans-obturator tape (TOT) or suprap

284 for immunomodulatory therapies, specifically vaginal therapies to treat women suffering from rUTI, pa

285 Our study demonstrates that vaginal tissue is exceptionally vulnerable to infection

286 (P < .001) in CVL, 75% and 71% (P < .001) in vaginal tissue, and 75% (P = .06) and 55% (P < .001) in

287 no viral suppression was seen in cervical or vaginal tissue.

288 to genistein on gene specific mRNA levels in vaginal tissue.

289 0% incidence, with infection observed in the vaginal tract at early time points.

290 D4+ T cells as primary targets of SIV during vaginal transmission.

291 Those animals that received only vaginal vaccinations had identical IgG but superior IgA

292 al and, separately, abdominal mesh repair of vaginal vault prolapse compared with vaginal non-mesh re

293 th vaginal and abdominal mesh procedures for vaginal vault prolapse repair are associated with simila

294 who was born in an ambulance by spontaneous vaginal vertex delivery.

295 beyond the hymen), and delivery method (any vaginal vs all caesarean sections).

296 Histological analysis of the upper vaginal wall indicated a signature of collagen fiber dis

297 mice were present in multiple layers of the vaginal wall, with older mice showing overall loss of in

298 ynthase (nNOS) in nerve fibers of the murine vaginal wall.

299 nfected with C. muridarum produced serum and vaginal wash antibodies and an antigen-specific gamma in

300 Here, we establish a mouse model of vaginal ZIKV infection and demonstrate that, unlike othe